Urology Care Foundation Announces 2025 Research Awards of Distinction
BALTIMORE, April 15, 2025 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world's leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2025 Research Awards of Distinction.
The awards acknowledge outstanding contributions to urological research, specifically in pediatrics and prostate cancer. They recognize the accomplishments of previous Urology Care Foundation grant recipients, celebrate the dedication of exemplary research mentors and highlight the efforts of talented early-career scholars.
'We're extremely proud to recognize the extraordinary contributions of this year's awardees,' said Harris M. Nagler, MD, Urology Care Foundation president. 'Their commitment to advancing urologic research to improve urological care is exemplary. The support of dedicated researchers is central to the Foundation's mission.'
Congratulations to this year's recipients:
John W. Duckett, Jr., MD Pediatric Urology Research Excellence Award
Andrew J. Kirsch, MD, clinical professor and chief of Pediatric Urology, Emory University School of Medicine
Established in 2009, the Duckett Award is named in honor of the late world-renowned pediatric urologist and professor and made possible through a fund established by Mrs. Peggy Duckett-Drach and the Societies for Pediatric Urology. The Duckett Award is presented annually to recognize outstanding work in the field of pediatric urology research.
Richard D. Williams, MD Prostate Cancer Research Excellence Award
Howard Scher, MD, head of Biomarker Development Program, Memorial Sloan Kettering Cancer Center and professor of medicine, Weill Cornell Medical College
Established in 2013, the Williams Award is named in honor of the late urologist, scientist, mentor and humanitarian. It's made possible through a fund established by Mrs. Beverly Williams. The Williams Award is presented annually to recognize outstanding and impactful research in the field of prostate cancer over the previous 10 years.
Distinguished Mentor Award
John L. Gore, MD, MS, professor, Department of Urology at University of Washington Medical Center, Fred Hutchinson Cancer Center
Established in 2003, the Distinguished Mentor Award recognizes researchers and physician-scientists who have an outstanding track record of fostering the next generation of research by continually providing an excellent training environment and guidance to early-career investigators.
Distinguished Scholar Alumnus Award
Robert Uzzo, MD, MBA, FACS, president and CEO, Fox Chase Cancer Center
Established in 2003, the Distinguished Scholar Alumnus Award recognizes former Urology Care Foundation Research Scholars who have achieved substantial impactful research and demonstrate an unwavering commitment to scholarship and academic leadership in the field.
Outstanding Graduate Scholar Award
Established in 2016, the Outstanding Graduate Scholar Award recognizes a one-year and two-year Research Scholar Award recipient completing their Urology Care Foundation-funded research. Awardees are chosen based on the quality and difficulty of the applicant's project, the potential impact of their studies, demonstrated research productivity, publications generated during the award period and the scholars' potential as future research leaders. Recipients of this award undergo a competitive application process and are selected by the AUA Research Council and Committees.
Venkat Ramakrishnan, MD, PhD, clinical fellow of Pediatric Urology at Boston Children's Hospital, Harvard Medical School and the Massachusetts Institute of Technology, has received a 2025 Outstanding Graduate Scholar Award for a one-year research project on the Development of a Novel Minimally Invasive Intravesical Drug-Delivery Platform to Address Neurogenic Bladder. It was conducted under the mentorship of Rosalyn Adam, PhD, Boston Children's Hospital, Harvard Medical School.
Asmaa El-Kenawi, PhD, assistant professor of Urology, Indiana University School of Medicine, Department of Urology, and Indiana University Melvin and Bren Simon Comprehensive Cancer Center, has received a 2025 Outstanding Graduate Scholar Award for a two-year research project on Identifying Immune Tumor Cell Metabolic Dependencies in Prostate Cancer. It was conducted under the mentorship of Kosj Yamoah, MD, PhD, Moffitt Cancer Center, Tampa, FL, and Michael Koch, MD, Indiana University School of Medicine Department of Urology.
'I'm inspired by the groundbreaking research being conducted by this year's awardees. Their innovative studies in pediatric urology and prostate cancer advance our scientific understanding and pave the way for significant improvements in patient care,' added Steven Kaplan, MD, chair of the AUA's Research Council. 'Their commitment to pushing the boundaries of urologic research heralds a bright future for our specialty and sets a new standard for clinical excellence.'
The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in April 2025. To learn more, visit AUAnet.org/researchhonors.
About the Urology Care Foundation: The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association. Collaborating with physicians, researchers, patients and the public, the Foundation supports and improves urologic clinical care by funding research, developing patient education and pursuing philanthropic support. To learn more about the Urology Care Foundation and its programs visit: UrologyHealth.org.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 25,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. www.AUAnet.org
Attachment
Corey Del Bianco Urology Care Foundation 443-689-4033 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ('Vaxart' or the 'Company'), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the 'Annual Meeting') in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders. Stockholders voted in favor of the following proposals in alignment with the Board of Directors' recommendations: Election of six director nominees to serve until the 2026 Annual Meeting of Stockholders Ratification of WithumSmith+Brown, PC as Vaxart's independent registered public accounting firm Stockholders voted against the following proposals at the Annual Meeting: An amendment to the Restated Certificate of Incorporation to effect a reverse stock split. The Company is evaluating its options as to next steps. On an advisory basis, the compensation for the Company's named executive officers as described in the proxy statement for the Annual Meeting, also known as 'say-on-pay' The final results are subject to verification by the inspector of elections. The final results will be reported on a Current Report on Form 8-K to be filed by Vaxart with the U.S. Securities and Exchange Commission. About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition, voting results from the Annual Meeting, Vaxart's plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Contact Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@ 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
KFSHRC Advances Smart Hospital Transformation through AI and Emerging Technologies
RIYADH, Saudi Arabia, June 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to redefine global healthcare through its Smart Hospital initiative, leveraging AI, simulation, and immersive technologies across its departments. These technologies have supported KFSHRC to enhance workforce training, clinical care, and operational efficiency. The Academic & Training Affairs (ATA) division is leading this transformation, deploying next-generation tools such as simulation labs, e-learning, and virtual reality (VR) to deliver hands-on, immersive training. These technologies allow healthcare professionals to rehearse complex procedures from emergency care to surgical planning, strengthening clinical preparedness and patient safety. The Patient Flow & Capacity Command Centre enhances operational efficiency by applying AI to forecast demand, manage resources, and monitor patient flow in real time. Since its launch, the Centre has completed over 170,000 interventions, cutting bed wait times from 32 to 6 hours and reducing emergency delays by 14%. In 2024 alone, the hospital received over 46,000 new patients and processed more than 79,000 referrals. Smart tools, such as the Noor robot, enhance the patient experience by providing real-time assistance and improving access to services. Across departments such as Radiology, Pathology, Genomics, and Oncology, AI enhances diagnosis, interpretation, early interventions and personalized care for complex diseases. Driving these innovations is KFSHRC's Centre for Healthcare Intelligence (CHI), which has developed over 20 AI applications in medical imaging, clinical decision support, and operations. In partnership with the Saudi Commission for Health Specialties, CHI also leads national AI training programs to build future-ready digital health talent. At the 2024 GAIN Summit CHI unveiled a generative AI platform to synthesize patient data, accelerate diagnostics, and streamline triage. KFSHRC ranks among Saudi Arabia's top 20 government entities in the 2025 Technology Adoption Readiness Index and received the 2024 Zimam Best AI Program Award, recognizing its leadership in AI, robotic surgery, and digital innovation. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. For more information, visit or contact our media team at mediacoverage@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
21 hours ago
- Business Upturn
Worker Protection from Heat Stress: Now More Than Ever, It's Up to Employers to Do The Right Thing
St. Paul, MN, June 13, 2025 (GLOBE NEWSWIRE) — With federal cost-cutting and deregulation reshaping workplace safety oversight, the responsibility to protect workers from extreme heat is falling squarely on employers. While OSHA's National Emphasis Program (NEP) on Heat Stress has been extended for another year, the long-anticipated federal heat stress standard is looking less likely than ever. That means worksites will need to rely on existing guidance, industry best practices, and—more than anything—their own commitment to doing what's right. 'The reality is, a federally mandated heat stress standard in the U.S. may not happen anytime soon,' says Greg Schrab, President at Ergodyne, a leader in safety work gear and heat stress prevention. 'But regulation should never be the reason we protect workers. Employers don't need a federal rule to tell them that heat stress is dangerous, or that simple, proven solutions can save lives.' With extreme heat becoming a predictable threat year after year, safety professionals are stepping up where federal regulations fall short—turning to resources like OSHA's NEP, ANSI/ASSP A10.50-2024, state regulations, and industry safety leaders to build and reinforce heat stress prevention programs that work. From implementing hydration and rest schedules to providing personal cooling gear, the industry's best practices are well-documented. The challenge for many employers isn't knowing what to do—it's making sure it gets done. Randy Milliron, Safety Manager for the City of Gillette, Wyoming, agrees. He points to time-tested basics as the foundation of his program. 'It will sound so rudimentary, but if you keep to the classics you can safely work outside when the thermostat starts to rise. Drinking plenty of fluids, monitoring urine output and color, taking breaks in the shade, and looking out for your co-workers are the key things to help you stay cool and hydrated.' To help worksites put prevention into practice, Ergodyne is expanding its cooling gear and heat stress solutions with new advancements in wearable cooling, flame-resistant cooling PPE, and turnkey heat stress prevention kits. But gear is only part of the equation. The St. Paul, MN-based worksite safety leader and cooling category pioneer is in the field working alongside employers to provide on-site education in support of company heat stress prevention programs. 'Unless you are attending safety conferences and rubbing elbows with the vendors who provide this type of PPE, you might not know of all the advancements that have been made in these product lines,' Milliron says. 'So, I believe it is necessary, if you are a safety professional, to find those subject-matter experts who specialize in cooling products and create long-lasting friendships with them.' Milliron has seen firsthand how proactive prevention can make a difference. 'Last summer we had a seasonal employee try to work through the early signs and symptoms of heat illness. By the time I arrived, he was in bad shape. We moved him into the air-conditioned office and applied ice packs and a cooling towel to his groin and neck. It took a very long time for his symptoms to subside, but the cooling towel did the trick at lowering his core body temperature.' By leveraging proven cooling solutions and industry-backed guidance, safety leaders can make sure their teams stay safe, stay productive, and stay protected—regardless of what happens at the federal level. 'In the absence of federal action, it's up to employers to step up,' says Lexi Engelbart, Product Manager at Ergodyne and Vice Chair of the International Safety Equipment Association's (ISEA) Heat Stress Solutions Group. 'Not because they have to, but because it's the right thing to do.' For more heat stress education, including signs, symptoms, and solutions, visit ABOUT ERGODYNE Since 1983, Tenacious Holdings, Inc. (dba Ergodyne, a Klein Tools Company) has pioneered the development of products that Make The Workplace A Betterplace™. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to provide protection, promote prevention and manage the elements for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head & Face Protection, Skullerz® Eye Protection, Trex® Traction, KREW'D® Skin Protection, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Gear and Tool Storage, and SHAX® Portable Work Shelters. Originally posted on: Attachment New Heat Stress Hazard Solutions Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
